日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Abstracts of Scientific Presentations: 2025 AALAS National Meeting Long Beach, California

科学报告摘要:2025 年美国实验生物学会 (AALAS) 全国会议,加利福尼亚州长滩市

Bonaca, Marc P; Catarig, Andrei-Mircea; Hansen, Yasemin; Houlind, Kim; Ramesh, Chethana Kalmady; Ludvik, Bernhard; Nordanstig, Joakim; Rasouli, Neda; Sourij, Harald; Verma, Subodh

Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis

在真实世界环境中,既往接受过胰高血糖素样肽-1受体激动剂治疗的2型糖尿病成人患者改用每周一次司美格鲁肽治疗:SURE项目事后分析

Rudofsky, Gottfried; Menzen, Markus; Potier, Louis; Catarig, Andrei-Mircea; Clark, Alice; Priyadarshini, Prachi; Abreu, Cristina

Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial

根据基线 2 型糖尿病特征评估司美格鲁肽治疗症状性外周动脉疾病的益处:来自 STRIDE 随机、安慰剂对照、双盲试验的启示

Rasouli, Neda; Guder Arslan, Ecenur; Catarig, Andrei-Mircea; Houlind, Kim; Ludvik, Bernhard; Nordanstig, Joakim; Sourij, Harald; Thomas, Sebastian; Verma, Subodh; Bonaca, Marc P

Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study

每周一次使用司美格鲁肽治疗 2 型糖尿病:来自 SURE 荷兰观察性研究的真实世界数据

Wolffenbuttel, Bruce H R; Brugts, Michel P; Catarig, Andrei-Mircea; Clark, Alice; Kok, Maarten; Lieverse, Aloysius G; van Soest, Jaap

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal-Bolus Insulin in Type 2 Diabetes

2型糖尿病患者中基础胰岛素联合每周一次司美格鲁肽与完全优化基础-餐时胰岛素方案的间接比较

Lingvay, Ildiko; Catarig, Andrei-Mircea; Lawson, Jack; Chubb, Barrie; Gorst-Rasmussen, Anders; Evans, Lyndon Marc

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany

每周一次索玛鲁肽治疗2型糖尿病的真实世界应用:来自德国索玛鲁肽真实世界证据(SURE)研究的结果

Menzen, Markus; Berentzen, Tina Landsvig; Catarig, Andrei-Mircea; Pieperhoff, Sebastian; Simon, Jörg; Jacob, Stephan

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups

每周一次索玛鲁肽在 2 型糖尿病患者中的真实世界应用:基于基线特征亚组的四项 SURE 研究数据的汇总分析

Yale, Jean-François; Bodholdt, Ulrik; Catarig, Andrei-Mircea; Catrina, Sergiu; Clark, Alice; Ekberg, Neda Rajamand; Erhan, Umut; Holmes, Patrick; Knudsen, Søren Tang; Liutkus, Joanne; Sathyapalan, Thozhukat; Schultes, Bernd; Rudofsky, Gottfried

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg

一项间接治疗比较研究,旨在评估司美格鲁肽 1.0 mg 与度拉糖肽 3.0 mg 和 4.5 mg 的疗效。

Pratley, Richard E; Catarig, Andrei-Mircea; Lingvay, Ildiko; Viljoen, Adie; Paine, Abby; Lawson, Jack; Chubb, Barrie; Gorst-Rasmussen, Anders; Miresashvili, Nino

Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study

在常规临床实践中,每周一次使用司美格鲁肽治疗2型糖尿病患者:来自SURE Canada多中心前瞻性观察研究的结果

Yale, Jean-François; Catarig, Andrei-Mircea; Grau, Katrine; Harris, Stewart; Klimek-Abercrombie, Agnieszka; Rabasa-Lhoret, Rémi; Reardon, Laura; Woo, Vincent; Liutkus, Joanne

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study

每周一次索玛鲁肽治疗2型糖尿病的真实世界应用:来自SURE UK多中心前瞻性观察研究的结果

Holmes, Patrick; Bell, Heather Elizabeth; Bozkurt, Karan; Catarig, Andrei-Mircea; Clark, Alice; Machell, Alena; Sathyapalan, Thozhukat